Literature DB >> 8660081

Low dose colestipol in adolescents with familial hypercholesterolaemia.

S Tonstad1, M Sivertsen, L Aksnes, L Ose.   

Abstract

The effects of orange flavoured colestipol granules, 10 g/day, in 37 boys and 29 girls aged 10-16 years with familial hypercholesterolaemia were examined first in an eight week double blind, placebo controlled protocol, then in open treatment for 44-52 weeks. All patients were on a low fat diet. Low density lipoprotein cholesterol levels were reduced by 19.5% by colestipol v 1.0% by placebo. Levels of serum folate, vitamin E, and carotenoids were reduced in the colestipol group, but not the vitamin E/cholesterol and carotenoid/cholesterol ratios or serum concentrations of vitamins A and D. After one year of colestipol, two thirds of the participants remained in the study, of whom half took > or = 80% of the prescribed dose. Those who took > or = 80% of the dose had a greater decrease in serum 25-hydroxyvitamin D levels than those who took < 80%. No adverse effects on weight gain or linear growth velocity were observed. Although low dose colestipol effectively reduces low density lipoprotein cholesterol levels, only a minority of adolescents adhered to the new formulation for one year. Folate and possibly vitamin D supplementation is recommended.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8660081      PMCID: PMC1511517          DOI: 10.1136/adc.74.2.157

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  24 in total

1.  Drug therapy in children and adolescents with familial hypercholesterolemia.

Authors:  E A Stein
Journal:  Prog Clin Biol Res       Date:  1988

Review 2.  Folate status assessment.

Authors:  L B Bailey
Journal:  J Nutr       Date:  1990-11       Impact factor: 4.798

Review 3.  Methods for assessment of vitamin A status.

Authors:  B A Underwood
Journal:  J Nutr       Date:  1990-11       Impact factor: 4.798

Review 4.  The use and interpretation of assays for vitamin D and its metabolites.

Authors:  M F Holick
Journal:  J Nutr       Date:  1990-11       Impact factor: 4.798

5.  Risk of angina pectoris and plasma concentrations of vitamins A, C, and E and carotene.

Authors:  R A Riemersma; D A Wood; C C Macintyre; R A Elton; K F Gey; M F Oliver
Journal:  Lancet       Date:  1991-01-05       Impact factor: 79.321

6.  Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia.

Authors:  H R Superko; P Greenland; R A Manchester; N A Andreadis; G Schectman; N H West; D Hunninghake; W L Haskell; J L Probstfield
Journal:  Am J Cardiol       Date:  1992-07-15       Impact factor: 2.778

7.  The use of different lipids to express serum tocopherol: lipid ratios for the measurement of vitamin E status.

Authors:  D I Thurnham; J A Davies; B J Crump; R D Situnayake; M Davis
Journal:  Ann Clin Biochem       Date:  1986-09       Impact factor: 2.057

8.  Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study.

Authors:  J F Brensike; R I Levy; S F Kelsey; E R Passamani; J M Richardson; I K Loh; N J Stone; R F Aldrich; J W Battaglini; D J Moriarty
Journal:  Circulation       Date:  1984-02       Impact factor: 29.690

9.  Fat-soluble vitamin concentrations in hypercholesterolemic children treated with colestipol.

Authors:  K B Schwarz; P D Goldstein; J L Witztum; G Schonfeld
Journal:  Pediatrics       Date:  1980-02       Impact factor: 7.124

10.  Long-term follow-up of children with familial hypercholesterolaemia treated with cholestyramine.

Authors:  R J West; J K Lloyd; J V Leonard
Journal:  Lancet       Date:  1980-10-25       Impact factor: 79.321

View more
  7 in total

Review 1.  Role of lipid-lowering pharmacotherapy in children.

Authors:  S Tonstad
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

Review 2.  A rational approach to treating hypercholesterolaemia in children. Weighing the risks and benefits.

Authors:  S Tonstad
Journal:  Drug Saf       Date:  1997-05       Impact factor: 5.606

Review 3.  Cardiovascular risk assessment and cholesterol management in adolescents: getting to the heart of the matter.

Authors:  Holly C Gooding; Sarah D de Ferranti
Journal:  Curr Opin Pediatr       Date:  2010-08       Impact factor: 2.856

Review 4.  The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia.

Authors:  Waleed Z Butt; Jennifer K Yee
Journal:  Curr Atheroscler Rep       Date:  2022-03-28       Impact factor: 5.113

Review 5.  Rational approach to the treatment for heterozygous familial hypercholesterolemia in childhood and adolescence: a review.

Authors:  L Iughetti; B Predieri; F Balli; S Calandra
Journal:  J Endocrinol Invest       Date:  2007-09       Impact factor: 4.256

Review 6.  The genetics of familial hypercholesterolemia and emerging therapies.

Authors:  Anja Vogt
Journal:  Appl Clin Genet       Date:  2015-01-28

Review 7.  Novel therapeutic targets and agents for pediatric dyslipidemia.

Authors:  Bhuvana Sunil; Christy Foster; Don P Wilson; Ambika P Ashraf
Journal:  Ther Adv Endocrinol Metab       Date:  2021-11-24       Impact factor: 3.565

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.